A generic drug is a pharmaceutical product, usually intended to be
interchangeable with an innovator product that is manufactured without a
license from the innovator company and marketed after the expiry date
of the patent or other exclusive rights.
Already prevalent in the U.S., Europe and much of the developing
world, generic drugs are now finding their way into previously untapped
markets such as Japan, largely driven by regulatory efforts to reduce
healthcare costs.
Browse Detail Report With TOC @ http://www.hexareports.com/report/the-generic-drugs-market
SNS Research estimates that the market for generic drugs will account
for nearly $350 Billion in revenue by the end of 2015. Despite
challenges relating to quality control and legal concerns, the market is
poised for significant growth in the coming years. The market is
expected to grow at a CAGR of 12% between 2015 and 2020, driven by
growth in both established and developing markets.
The “Generic Drugs Market: 2015 – 2030 – Opportunities, Challenges,
Strategies & Forecasts” report presents an in-depth assessment of
the generic drugs ecosystem including technology, economics, key trends,
market drivers, challenges, investment potential, regulatory landscape,
leading therapies, opportunities, future roadmap, value chain,
ecosystem player profiles and strategies. The report also presents
market size forecasts for generic drugs from 2015 through to 2030. The
forecasts are segmented for over 10 therapeutic areas, 3 brand
classifications, 5 regions and 25 leading countries.
The report comes with an associated Excel datasheet suite covering
quantitative data from all numeric forecasts presented in the report.
Key Findings:
The report has the following key findings:
* Generic drugs will account for nearly $350 Billion in revenue by the
end of 2015. The market is further expected to grow at a CAGR of 12%
over the next five years.
* As the market consolidates, larger players continue to grow their
market share on the heels of acquisitions and mergers. Well established
players are particularly keen to capitalize on joint ventures in
untapped markets such as Japan.
* In order to overcome low margins, some generic drug manufacturers
are venturing into the super generics opportunity. Sold for a
significantly higher price than their pure generic counterparts, super
generics account for 18% of all spending on generic drugs.
* In a bid to control costs and expand their global reach, generic
drug manufacturers are complementing their existing manufacturing and
R&D locations with sites in low cost countries such as India, China
and Russia.
* Driven by the cost saving potential of biosimilar drugs, a number of
countries have established regulatory pathways for their approval. We
estimate that approved biosimilar drugs will account for more than $20
Billion in revenue by the end of 2020.
Request A Sample copy of This Report @ http://www.hexareports.com/sample/47192
Topics Covered:
The report covers the following topics:
* Generic drugs ecosystem
* Market drivers and barriers
* Technology, economics and key trends
* Pure, branded and super generics
* Analysis of key therapeutic areas and leading generic drugs
* Regulatory landscape of generic drugs throughout the globe
* Industry roadmap and value chain
* Profiles and strategies of over 130 leading ecosystem players, including generic and innovator drug manufacturers
* Strategic recommendations for ecosystem players
* Market analysis and forecasts from 2015 till 2030
Table Of Content
1 Chapter 1: Introduction
1.1 Executive Summary
1.2 Topics Covered
1.3 Historical Revenue & Forecast Segmentation
1.4 Key Questions Answered
1.5 Key Findings
1.6 Methodology
1.7 Target Audience
1.8 Companies & Organizations Mentioned
2 Chapter 2: An Overview of Generic Drugs
2.1 What is a Generic Drug?
2.2 Reserve Engineering: How Are Generics Conceived?
2.3 The Concept of Bioequivalence: Are Generics the Same as Innovator Drugs?
2.4 The Question of Brand Quality: Are Generics as Efficient as their Innovator Counterparts?
2.5 Economics: Price Comparison
2.6 Brand Classification: Pure vs. Branded Generics
2.7 Market Growth Drivers
2.8 Market Barriers
Browse All Pharmaceutical Market Research Related Reports @ http://www.hexareports.com/category/pharmaceutical-market
3 Chapter 3: Regulatory Landscape
3.1 Regional Outlook
3.2 International Initiatives
4 Chapter 4: Drug Class Availability & Leading Therapies
4.1 Drug Class Availability
4.2 Leading Generic Drugs
5 Chapter 5: Generic Drugs Industry Roadmap & Value Chain
5.1 Industry Roadmap
5.2 Value Chain
6 Chapter 6: Key Market Players
6.1 Abbott Laboratories
6.2 AbbVie
6.3 ACETO Corporation
6.4 Acino Holding
6.5 Actavis
6.6 Actelion
6.7 Adcock Ingram
6.8 Ajinomoto
6.9 Akron
Browse Full Report @ http://www.hexareports.com/report/the-generic-drugs-market
About Us:
Hexa Reports is a market research and consulting organization,
offering industry reports, custom research and consulting services to a
host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients
obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Website: http://www.hexareports.com/
No comments:
Post a Comment